Synthetic immunology: modulating the human immune system.

Humans have manipulated the immune system to dampen or boost the immune response for thousands of years. As our understanding of fundamental immunology and biotechnological methodology accumulates, we can capitalize on this combined knowledge to engineer biological devices with the aim of rationally manipulating the immune response. We address therapeutic approaches based on the principles of synthetic immunology that either ameliorate disorders of the immune system by interfering with the immune response, or improve diverse pathogenic conditions by exploiting immune cell effector functions. We specifically highlight synthetic proteins investigated in preclinical and clinical trials, summarize studies that have used engineered immune cells, and finish with a discussion of possible future therapeutic concepts.

[1]  C. Polman,et al.  Natalizumab: bench to bedside and beyond. , 2013, JAMA neurology.

[2]  M. Vogel,et al.  Accelerated dissociation of IgE-FcεRI complexes by disruptive inhibitors actively desensitizes allergic effector cells. , 2014, The Journal of allergy and clinical immunology.

[3]  Martin Fussenegger,et al.  Smart medication through combination of synthetic biology and cell microencapsulation. , 2012, Metabolic engineering.

[4]  D. Furst Anakinra: review of recombinant human interleukin-I receptor antagonist in the treatment of rheumatoid arthritis. , 2004, Clinical therapeutics.

[5]  P. Dilger,et al.  Engineering of the gut commensal bacterium Bacteroides ovatus to produce and secrete biologically active murine interleukin‐2 in response to xylan , 2005, Journal of applied microbiology.

[6]  M. Merino,et al.  T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[7]  J. Chatel,et al.  Engineering lactococci and lactobacilli for human health. , 2013, Current opinion in microbiology.

[8]  Michel Sadelain,et al.  Hematopoietic stem cell engineering at a crossroads. , 2012, Blood.

[9]  Raphael Sandaltzopoulos,et al.  Chimeric Antigen Receptor T Cells with Dissociated Signaling Domains Exhibit Focused Antitumor Activity with Reduced Potential for Toxicity In Vivo , 2013, Cancer Immunology Research.

[10]  Jianren Gu,et al.  An EpCAM/CD3 bispecific antibody efficiently eliminates hepatocellular carcinoma cells with limited galectin-1 expression , 2014, Cancer Immunology, Immunotherapy.

[11]  L. Naldini,et al.  CD4+ T Cells from IPEX Patients Convert into Functional and Stable Regulatory T Cells by FOXP3 Gene Transfer , 2013, Science Translational Medicine.

[12]  Bernd Hauck,et al.  Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. , 2013, The New England journal of medicine.

[13]  E. Remaut,et al.  Formatted anti-tumor necrosis factor alpha VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis. , 2006, Arthritis and rheumatism.

[14]  M. Clark,et al.  Antibody humanization: a case of the 'Emperor's new clothes'? , 2000, Immunology today.

[15]  Thomas Singer,et al.  The safety and side effects of monoclonal antibodies , 2010, Nature Reviews Drug Discovery.

[16]  Christian Bailly,et al.  Strategies and challenges for the next generation of therapeutic antibodies , 2010, Nature Reviews Immunology.

[17]  M. Kay State-of-the-art gene-based therapies: the road ahead , 2011, Nature Reviews Genetics.

[18]  M. Pirmohamed,et al.  Challenges and approaches for the development of safer immunomodulatory biologics , 2013, Nature Reviews Drug Discovery.

[19]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[20]  David A Spiegel,et al.  Grand challenge commentary: Synthetic immunology to engineer human immunity. , 2010, Nature chemical biology.

[21]  N. Restifo,et al.  Reassessing target antigens for adoptive T cell therapy , 2013, Nature Biotechnology.

[22]  Vibha Jawa,et al.  T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation. , 2013, Clinical immunology.

[23]  Christina D Smolke,et al.  Genetic control of mammalian T-cell proliferation with synthetic RNA regulatory systems , 2010, Proceedings of the National Academy of Sciences.

[24]  S. Rosenberg,et al.  Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. , 2009, Blood.

[25]  Jin Ma,et al.  Therapeutic Inflammatory Monocyte Modulation Using Immune-Modifying Microparticles , 2014, Science Translational Medicine.

[26]  C. Heeschen,et al.  EpCAM/CD3-Bispecific T-cell Engaging Antibody MT110 Eliminates Primary Human Pancreatic Cancer Stem Cells , 2011, Clinical Cancer Research.

[27]  H. Simon,et al.  Living and dying for inflammation: neutrophils, eosinophils, basophils. , 2013, Trends in immunology.

[28]  J. Bartlett,et al.  CCR5 as a Natural and Modulated Target for Inhibition of HIV , 2013, Viruses.

[29]  Martin Fussenegger,et al.  Self-sufficient control of urate homeostasis in mice by a synthetic circuit , 2010, Nature Biotechnology.

[30]  M. Zurini,et al.  Current strategies in antibody engineering: Fc engineering and pH-dependent antigen binding, bispecific antibodies and antibody drug conjugates. , 2012, Biotechnology journal.

[31]  P. Kufer,et al.  Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells. , 2009, Leukemia research.

[32]  L. Naldini Ex vivo gene transfer and correction for cell-based therapies , 2011, Nature Reviews Genetics.

[33]  H. Gendelman,et al.  Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery. , 2006, Blood.

[34]  N. Popitsch,et al.  CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients , 2013, Clinical Cancer Research.

[35]  J. Hess,et al.  Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients , 2010, British journal of clinical pharmacology.

[36]  Karolina Palucka,et al.  Cancer immunotherapy via dendritic cells , 2012, Nature Reviews Cancer.

[37]  P. Moore,et al.  Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma. , 2011, Blood.

[38]  J. P. McCoy,et al.  Reduction of GVHD and enhanced antitumor effects after adoptive infusion of alloreactive Ly49-mismatched NK cells from MHC-matched donors. , 2007, Blood.

[39]  A. Petrov,et al.  Omalizumab and hypersensitivity reactions , 2013, Current opinion in allergy and clinical immunology.

[40]  Jeffrey A Hubbell,et al.  Engineering Approaches to Immunotherapy , 2012, Science Translational Medicine.

[41]  Michel Sadelain,et al.  PD-1– and CTLA-4–Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Target Immunotherapy Responses , 2013, Science Translational Medicine.

[42]  Vanessa Taupin,et al.  Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo , 2010, Nature Biotechnology.

[43]  Jérôme Larghero,et al.  Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia , 2010, Nature.

[44]  P. Linsley,et al.  The clinical utility of inhibiting CD28‐mediated costimulation , 2009, Immunological reviews.

[45]  A. Bagg,et al.  Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. , 2011, The New England journal of medicine.

[46]  Steven A. Rosenberg,et al.  Adoptive immunotherapy for cancer: harnessing the T cell response , 2012, Nature Reviews Immunology.

[47]  Michaela Gebauer,et al.  Anticalins small engineered binding proteins based on the lipocalin scaffold. , 2012, Methods in enzymology.

[48]  Christopher G. Parker,et al.  Antibody-recruiting molecules: an emerging paradigm for engaging immune function in treating human disease. , 2012, ACS chemical biology.

[49]  F. Lienert,et al.  Synthetic biology in mammalian cells: next generation research tools and therapeutics , 2014, Nature Reviews Molecular Cell Biology.

[50]  Soong Ho Um,et al.  Therapeutic cell engineering using surface-conjugated synthetic nanoparticles , 2010, Nature Medicine.

[51]  Richard A Fekete,et al.  Toward a live microbial microbicide for HIV: commensal bacteria secreting an HIV fusion inhibitor peptide. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[52]  S. Chimenti,et al.  Adalimumab in the Treatment of Immune-Mediated Diseases , 2014, International journal of immunopathology and pharmacology.

[53]  A. Melcher,et al.  Cell carriers for oncolytic viruses: Fed Ex for cancer therapy. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[54]  M. Sadelain,et al.  Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[55]  S. Elledge,et al.  The DNA damage response: making it safe to play with knives. , 2010, Molecular cell.

[56]  D. Chelius,et al.  Structural and functional characterization of the trifunctional antibody catumaxomab , 2010, mAbs.

[57]  C. Barbas,et al.  ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. , 2013, Trends in biotechnology.

[58]  J. Galipeau,et al.  Mechanisms of immune modulation by mesenchymal stromal cells and clinical translation. , 2013, Current molecular medicine.

[59]  W. Murphy,et al.  Advantages and clinical applications of natural killer cells in cancer immunotherapy , 2013, Cancer Immunology, Immunotherapy.

[60]  J. Kocik,et al.  Synthetic immunostimulatory oligonucleotides in experimental and clinical practice , 2012, Pharmacological reports : PR.

[61]  J. Teillaud From whole monoclonal antibodies to single domain antibodies: think small. , 2012, Methods in molecular biology.

[62]  Pamela A Silver,et al.  Enhancement of Cell Type Specificity by Quantitative Modulation of a Chimeric Ligand* , 2008, Journal of Biological Chemistry.

[63]  M. Lebwohl,et al.  The benefit/risk profile of TNF-blocking agents: findings of a consensus panel. , 2005, Seminars in arthritis and rheumatism.

[64]  M. Friedrich,et al.  Regression of Human Prostate Cancer Xenografts in Mice by AMG 212/BAY2010112, a Novel PSMA/CD3-Bispecific BiTE Antibody Cross-Reactive with Non-Human Primate Antigens , 2012, Molecular Cancer Therapeutics.

[65]  Benjamin Rhau,et al.  Synthetic control of mammalian-cell motility by engineering chemotaxis to an orthogonal bioinert chemical signal , 2014, Proceedings of the National Academy of Sciences.

[66]  M. E. Bonk,et al.  Rilonacept (arcalyst), an interleukin-1 trap for the treatment of cryopyrin-associated periodic syndromes. , 2009, P & T : a peer-reviewed journal for formulary management.

[67]  P. Kantoff,et al.  Sipuleucel-T immunotherapy for castration-resistant prostate cancer. , 2010, The New England journal of medicine.

[68]  L. Cosler,et al.  Pegfilgrastim: a review of the pharmacoeconomics for chemotherapy-induced neutropenia , 2012, Expert review of pharmacoeconomics & outcomes research.

[69]  S. Magez,et al.  Novel therapy based on camelid nanobodies. , 2013, Therapeutic delivery.

[70]  David L Porter,et al.  Chimeric antigen receptor therapy for cancer. , 2014, Annual review of medicine.

[71]  Wei-Ting Hwang,et al.  Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. , 2014, The New England journal of medicine.

[72]  Jos W. M. van der Meer,et al.  Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases , 2012, Nature Reviews Drug Discovery.

[73]  J. Orange,et al.  Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases , 2008, Nature Biotechnology.

[74]  J. Mitchell,et al.  Pharmacology and therapeutic potential of interferons. , 2012, Pharmacology & therapeutics.

[75]  M. Suarez‐Almazor,et al.  Biologics for rheumatoid arthritis: an overview of Cochrane reviews , 2009, The Cochrane database of systematic reviews.

[76]  Aoshuang Chen,et al.  Arming tumor-reactive T cells with costimulator B7-1 enhances therapeutic efficacy of the T cells. , 2006, Cancer research.

[77]  W. Stemmer,et al.  Multivalent avimer proteins evolved by exon shuffling of a family of human receptor domains , 2005, Nature biotechnology.

[78]  H. Simon,et al.  Protein overexpression following lentiviral infection of primary mature neutrophils is due to pseudotransduction. , 2011, Journal of immunological methods.

[79]  Wendell A. Lim,et al.  Bacterial Virulence Proteins as Tools to Rewire Kinase Pathways in Yeast and Immune Cells , 2012, Nature.

[80]  Luca Biasco,et al.  Lentiviral Hematopoietic Stem Cell Gene Therapy in Patients with Wiskott-Aldrich Syndrome , 2013, Science.

[81]  S. Rosenberg,et al.  Bcl-2 overexpression enhances tumor-specific T-cell survival. , 2005, Cancer research.

[82]  Martin Fussenegger,et al.  A synthetic multifunctional mammalian pH sensor and CO2 transgene-control device. , 2014, Molecular cell.

[83]  T. Wurch,et al.  Novel protein scaffolds as emerging therapeutic proteins: from discovery to clinical proof-of-concept. , 2012, Trends in biotechnology.

[84]  Michel Sadelain,et al.  Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells , 2012, Nature Biotechnology.

[85]  R. Hansen,et al.  Efficacy and safety of anakinra for the treatment of rheumatoid arthritis: an update of the Oregon Drug Effectiveness Review Project , 2009, Biologics : targets & therapy.

[86]  A. Vatrella,et al.  The potential of biologics for the treatment of asthma , 2012, Nature Reviews Drug Discovery.

[87]  P. Kufer,et al.  Blinatumomab: a historical perspective. , 2012, Pharmacology & therapeutics.

[88]  P. Robbins,et al.  Regulation of immune responses by extracellular vesicles , 2014, Nature Reviews Immunology.

[89]  M. Kalos,et al.  Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. , 2013, Immunity.

[90]  P. Baeuerle,et al.  Targeting T cells to tumor cells using bispecific antibodies. , 2013, Current opinion in chemical biology.

[91]  S. Rosenberg,et al.  Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[92]  M. McDermott Rilonacept in the treatment of chronic inflammatory disorders. , 2009, Drugs of today.

[93]  NK cell-based immunotherapy for malignant diseases , 2013, Cellular and Molecular Immunology.

[94]  M. Little,et al.  A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells , 2014, mAbs.

[95]  M. Coffey,et al.  Internalization of Oncolytic Reovirus by Human Dendritic Cell Carriers Protects the Virus from Neutralization , 2011, Clinical Cancer Research.

[96]  T. Daniels,et al.  Antibody–cytokine fusion proteins: applications in cancer therapy , 2008, Expert opinion on biological therapy.

[97]  C. Cordon-Cardo,et al.  Prostate-specific membrane antigen expression in normal and malignant human tissues. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[98]  S. Muyldermans,et al.  Nanobody-based products as research and diagnostic tools. , 2014, Trends in biotechnology.

[99]  M. Little,et al.  T and NK cells of B cell NHL patients exert cytotoxicity against lymphoma cells following binding of bispecific tetravalent antibody CD19 × CD3 or CD19 × CD16 , 2012, Cancer Immunology, Immunotherapy.

[100]  Atique U. Ahmed,et al.  Tumor-targeted, systemic delivery of therapeutic viral vectors using hitchhiking on antigen-specific T cells , 2005, Nature Medicine.

[101]  J. Jurcic What Happened to Anti-CD33 Therapy for Acute Myeloid Leukemia? , 2012, Current Hematologic Malignancy Reports.

[102]  David L. Porter,et al.  T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia , 2011, Science Translational Medicine.

[103]  A. Henn,et al.  Preclinical Characterization of AMG 330, a CD3/CD33-Bispecific T-Cell–Engaging Antibody with Potential for Treatment of Acute Myelogenous Leukemia , 2014, Molecular Cancer Therapeutics.

[104]  S. Welsh,et al.  The clinical use of granulocyte-colony stimulating factor. , 2014, British journal of hospital medicine.

[105]  M. Vogel,et al.  Accelerated Disassembly of IgE:Receptor Complexes by a Disruptive Macromolecular Inhibitor , 2012, Nature.

[106]  R. Kontermann Antibody-cytokine fusion proteins. , 2012, Archives of biochemistry and biophysics.

[107]  Lei Dong,et al.  Harnessing the power of macrophages/monocytes for enhanced bone tissue engineering. , 2013, Trends in biotechnology.

[108]  R. Maciuca,et al.  Targeting membrane-expressed IgE B cell receptor with an antibody to the M1 prime epitope reduces IgE production , 2014, Science Translational Medicine.

[109]  C. Horak,et al.  Nivolumab plus ipilimumab in advanced melanoma. , 2013, The New England journal of medicine.

[110]  M. Sadelain,et al.  Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. , 2012, Blood.

[111]  F. Marincola,et al.  IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. , 2011, The Journal of clinical investigation.

[112]  Darrell J Irvine,et al.  Enhancing Cell therapies from the Outside In: Cell Surface Engineering Using Synthetic Nanomaterials. , 2011, Nano today.

[113]  Martin Fussenegger,et al.  A closed-loop synthetic gene circuit for the treatment of diet-induced obesity in mice , 2013, Nature Communications.

[114]  Darrell J Irvine,et al.  Engineering synthetic vaccines using cues from natural immunity. , 2013, Nature materials.

[115]  Martin Fussenegger,et al.  A designer cell-based histamine-specific human allergy profiler , 2014, Nature Communications.

[116]  J. Wolchok,et al.  Annals of the New York Academy of Sciences Development of Ipilimumab: a Novel Immunotherapeutic Approach for the Treatment of Advanced Melanoma , 2022 .

[117]  F. Stivala,et al.  Understanding rituximab function and resistance: implications for tailored therapy. , 2011, Frontiers in bioscience.